Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 5 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

L-Arginine–tadalafil combo effective for diabetics with erectile dysfunction

09 Sep 2019

The combination of L-Arginine and tadalafil improves erectile function among diabetic men with erectile dysfunction, a recent study has found.

Researchers conducted a double-blinded, randomized, controlled clinical trial including 108 diabetic men who received L-Arginine alone (n=27; mean age, 43.19±4.8 years), tadalafil alone (n=27; mean age, 43.04±5.9 years), both medications (n=27; mean age, 45.33±4.3 years) or placebo (n=27; mean age, 43.11±4.6 years). The International Index of Erectile Function 5-item (IIEF-5) questionnaire was used to measure erectile function.

Scores in the IIEF-5 improved after treatment with both L-Arginine (12.22±1.5 to 18.33±1.8) and tadalafil (12.44±1.4 to 20.07±1.4), such that changes were significantly greater than those in the placebo group (p<0.001 for both). The same was true for participants who received both medications (13.67±2.2 to 23.52±1.3; p<0.001).

Between-treatment comparisons showed that the change in IIEF-5 scores was significantly greater in the tadalafil vs L-Arginine group (p<0.001), but that the combination was significantly superior to both tadalafil alone (percent change: 82.88±7.1 percent vs 62.89±3.7 percent; p=0.007) and L-Arginine alone (percent change: 52.21±4.3 percent vs 82.88±7.1 percent; p<0.001).

Similar patterns of change were reported for total testosterone concentrations, which significantly increased in all treated participants, but not in those who received placebo. Tadalafil again elicited significantly greater changes than L-Arginine (p<0.001), while the treatment combination emerged as the most effective intervention (p<0.011).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 5 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.